I have been waiting for this one for a long time. ShK-186 has entered phase 1, in the Netherlands.

ShK-186 inhibits the Kv1.3 potassium ion channel. Kineta’s program is the first Kv1.3-specific inhibitor advanced into the clinic. Kv1.3 has been a target of industry efforts for its role in instigating activation of effector memory T-cells, which are major mediators of autoimmune disease. Kineta scientific advisor and University of California, Irvine Professor, K. George Chandy and his collaborators invented ShK-186 by modifying natural sea anemone-derived peptide inhibitors of Kv1.3. ShK-186 can reduce disease symptoms and pathology in animal models of MS without broadly suppressing the immune system.


1 Comment »

  1. Ken North said

    As a representative of Kineta, I would like to update all on the progress of this first-in-human first-in-class clinical trial: The first cohort received dosing on 10-10-12. To date we have not received any reports of safety concerns.

    If people have questions regarding this drug candidate or about Kineta, please feel free to contact me.

    Ken North
    Vice President, Capital Acquisition
    Kineta, Inc.

RSS feed for comments on this post · TrackBack URI

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: